Abstract |
The ability of SkQ1 eye drops to slow down the cataract development is demonstrated on the senescence-accelerated OXYS rats: the SkQ1 treatment leads to the considerable improvement of the lens condition as compared to the control group. The comparison of the chaperone activities of α- crystallins isolated from the rat lenses did not reveal significant difference between SkQ1-treated and control rats. The contents of major metabolites (23 compounds) in lenses of SkQ1-treated and untreated rats are also very similar, though the concentration of reduced glutathione (GSH) in lenses of SkQ1-treated rats is 12% lower. This difference may be attributed to the reduction of the oxidative stress under action of SkQ1 eye drops, and to the decreased requirement to produce high amounts of this antioxidant.
|
Authors | L V Yanshole, V V Yanshole, O A Snytnikova, A Zh Fursova, N G Kolosova, Yu P Tsentalovich, R Z Sagdeev |
Journal | Doklady. Biochemistry and biophysics
(Dokl Biochem Biophys)
Vol. 464
Pg. 341-5
( 2015)
ISSN: 1608-3091 [Electronic] United States |
PMID | 26518564
(Publication Type: Journal Article)
|
Chemical References |
- 10-(6'-plastoquinonyl)decyltriphenylphosphonium
- Free Radical Scavengers
- Ophthalmic Solutions
- alpha-Crystallins
- beta-Crystallins
- Glutathione
- Plastoquinone
|
Topics |
- Aging
(drug effects, metabolism)
- Animals
- Cataract
(drug therapy, metabolism)
- Disease Models, Animal
- Free Radical Scavengers
(administration & dosage)
- Glutathione
(metabolism)
- Kinetics
- Lens, Crystalline
(drug effects, metabolism)
- Ophthalmic Solutions
- Oxidative Stress
(drug effects, physiology)
- Plastoquinone
(administration & dosage, analogs & derivatives)
- Protein Multimerization
- Rats
- alpha-Crystallins
(metabolism)
- beta-Crystallins
(metabolism)
|